FDA Oncology Announcements

Bcl-2 inhibitor × Myeloid × Clear all

2 Announcements

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia

Trial: Viale-a
Drugs: VENCLEXTA (venetoclax) · Bcl-2 inhibitor, azacitidine · DNA methyltransferase inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia

Trial: Viale-a
Drug: venetoclax · Bcl-2 inhibitor
Conditions: MyeloidOther hematologic neoplasm